BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 20, 2024
See today's BioWorld
Home
» Strike one for ASTRAL as guadecitabine swings and misses in front-line AML
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Strike one for ASTRAL as guadecitabine swings and misses in front-line AML
Aug. 1, 2018
By
Marie Powers
No Comments
Guadecitabine (SGI-110), the prize in Otsuka Pharmaceutical Co. Ltd.'s 2013 pick-up of Astex Pharmaceuticals Inc. for $886 million in cash, failed its first pivotal test.
BioWorld